Syndax Pharmaceuticals (SNDX) reported $172M in revenue for fiscal 2025, +627.8% year on year. That ranks #2724 by revenue among 2853 SEC filers and #300 in Healthcare. It posted a net loss of −$285M for the same year. Revenue has grown 73.3% a year on average since 2016 ($1.2M then). The fiscal 2025 balance sheet shows $530M in total assets and $135M in cash.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $172M | +627.8% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | −$273M | +$66.6M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$285M | +$33.4M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$323M | −$48.1M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $187,000 | +$187,000 | FY20252025-12-31 |
| Total assetsAssets | $530M | −26.9% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $64.6M | −77.6% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $135M | −12.4% | FY20252025-12-31 |
| Long-term debt | Not reported | — |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $64.9M | −$42.7M | Open → |
| Q2 20262026-06-30 | $72.8M | −$49.4M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Syndax Pharmaceuticals Inc
- Ticker
- SNDX
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001395937
Filings
- 10-QAug 4, 2026Open filing →
- 10-QApr 30, 2026Open filing →
- 10-KFeb 26, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| HeartflowHTFL | $176M | −$117M |
| Phathom PharmaceuticalsPHAT | $175M | −$221,250 |
| SBC Medical GroupSBC | $174M | $51.0M |
| Syndax PharmaceuticalsSNDX | $172M | −$285M |
| RegenxbioRGNX | $170M | −$194M |
| Ginkgo BioworksDNA | $170M | −$313,000 |
| MarimedMRMD | $160M | −$14.5M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Syndax Pharmaceuticals — Key figures |url=https://companiesranked.com/en/company/syndax-pharmaceuticals |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Syndax Pharmaceuticals — Key figures. CompaniesRanked. https://companiesranked.com/en/company/syndax-pharmaceuticalsBibTeX
@misc{companiesranked-en-company-syndax-pharmaceuticals-2026,
author = {{CompaniesRanked}},
title = {{Syndax Pharmaceuticals — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/syndax-pharmaceuticals}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-076536 · February 26, 2026
{{cite web |title=Syndax Pharmaceuticals — Key figures — 10-K (0001193125-26-076536) |url=https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/sndx-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.